Is G1 Therapeutics Inc halal to invest in?

As of July 2026, G1 Therapeutics Inc GTHX is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is G1 Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes G1 Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of G1 Therapeutics Inc?

Muslim investors may consider investing in G1 Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is G1 Therapeutics Inc classified as HALAL?

Musaffa determines the Shariah status of G1 Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for G1 Therapeutics Inc updated?

The Shariah compliance status of G1 Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like G1 Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of G1 Therapeutics Inc?

You can check the latest Shariah compliance status of G1 Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

G1 Therapeutics Inc GTHX

Last Updated: Sep 17, 12:00 AM·BE

GTHX Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, G1 Therapeutics Inc is classified as halal.

HALAL

Report Source: 2024 2nd Quarter Report

G1 Therapeutics Inc. Stock Analysis GTHX

Germany Health Care Small Cap Report: Q2, 2024

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 100 full-time employees. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.

Key Statistics of G1 Therapeutics Inc (GTHX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$7.14$7.16

Today's Open

$7.15

Volume

1.27M

P/E Ratio (TTM)

52 Week Range

$1.09$8.40

Market Cap

377.22M

Avg. Volume

1.74M

Dividend Yield

Financial Metrics & Statements of G1 Therapeutics Inc (GTHX)

Super Investors Invested in G1 Therapeutics Inc (GTHX)

FAQ's for G1 Therapeutics Inc (GTHX)

As of July 2026, G1 Therapeutics Inc GTHX is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes G1 Therapeutics Inc using these criteria to determine its compliance status.
Muslim investors may consider investing in G1 Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of G1 Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of G1 Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of G1 Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.